Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

RxSight (RXST) EBT (2020 - 2025)

Historic EBT for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to -$9.8 million.

  • RxSight's EBT fell 5503.56% to -$9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.7 million, marking a year-over-year decrease of 1624.4%. This contributed to the annual value of -$27.4 million for FY2024, which is 4359.74% up from last year.
  • RxSight's EBT amounted to -$9.8 million in Q3 2025, which was down 5503.56% from -$11.8 million recorded in Q2 2025.
  • RxSight's EBT's 5-year high stood at -$5.9 million during Q4 2024, with a 5-year trough of -$17.6 million in Q1 2022.
  • In the last 5 years, RxSight's EBT had a median value of -$12.4 million in 2023 and averaged -$11.6 million.
  • As far as peak fluctuations go, RxSight's EBT tumbled by 15987.3% in 2021, and later soared by 5599.51% in 2024.
  • Over the past 5 years, RxSight's EBT (Quarter) stood at -$15.7 million in 2021, then increased by 0.88% to -$15.6 million in 2022, then surged by 41.08% to -$9.2 million in 2023, then soared by 35.56% to -$5.9 million in 2024, then crashed by 65.45% to -$9.8 million in 2025.
  • Its last three reported values are -$9.8 million in Q3 2025, -$11.8 million for Q2 2025, and -$8.2 million during Q1 2025.